Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
1.450
+0.020 (1.40%)
Feb 21, 2025, 4:00 PM EST - Market closed
Lexaria Bioscience Employees
Lexaria Bioscience had 7 employees as of August 31, 2024. The number of employees increased by 2 or 40.00% compared to the previous year.
Employees
7
Change (1Y)
2
Growth (1Y)
40.00%
Revenue / Employee
$70,989
Profits / Employee
-$1,045,674
Market Cap
25.45M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Aug 31, 2024 | 7 | 2 | 40.00% |
| Aug 31, 2023 | 5 | -2 | -28.57% |
| Aug 31, 2022 | 7 | 1 | 16.67% |
| Aug 31, 2021 | 6 | 2 | 50.00% |
| Aug 31, 2020 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
LEXX News
- 2 days ago - Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide - Accesswire
- 11 days ago - Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy - Accesswire
- 15 days ago - Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway - TheNewswire
- 17 days ago - Lexaria Updates its Ongoing Human Study GLP-1-H24-4 - TheNewswire
- 23 days ago - Lexaria Releases Annual Letter from the CEO - Accesswire
- 5 weeks ago - Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval - Accesswire
- 5 weeks ago - Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R) - Accesswire
- 2 months ago - Lexaria's Registered GLP-1 Study #4 Begins Dosing - Accesswire